Larvol Delta - ACELYRIN-INC-Announces-Longterm-32Week-Data-from-the-Phase-2b-Trial-of-Izokibep-in-Hidradenitis-Suppurativa-Demonstrating-Sustained-Responses-and-Deepening-Clinical-Benet--Improving-Quality-of-Life-for-Patients

izokibep (ABY-035) - ACELYRIN

https://www.biospace.com/article/releases/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients/

Mar 11, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next